Abstract | AIM: METHODS: Twenty-six patients who received ETV plus HBIG (ETV group) after LDLT for hepatitis B virus (HBV)-related end-stage liver disease were analyzed by comparing with 63 control patients who had received LAM plus HBIG ( LAM group). RESULTS: The survival rates of the patients treated with ETV plus HBIG was 73% after both 1 and 3 years, and there was no statistical difference between the patients in the ETV group and LAM group. No HBV recurrence was detected during the median follow-up period of 25.1 months in the ETV group, whereas the HBV recurrence rate was 4% at 3 years and 6% at 5 years in the LAM group. No patients had adverse effects related to ETV administration. CONCLUSION: ETV combined with HBIG provides effective and safe prophylaxis in preventing hepatitis B recurrence after LDLT.
|
Authors | Yoshihide Ueda, Hiroyuki Marusawa, Toshimi Kaido, Yasuhiro Ogura, Kohei Ogawa, Atsushi Yoshizawa, Koichiro Hata, Yasuhiro Fujimoto, Norihiro Nishijima, Tsutomu Chiba, Shinji Uemoto |
Journal | Hepatology research : the official journal of the Japan Society of Hepatology
(Hepatol Res)
Vol. 43
Issue 1
Pg. 67-71
(Jan 2013)
ISSN: 1386-6346 [Print] Netherlands |
PMID | 22548744
(Publication Type: Journal Article)
|
Copyright | © 2012 The Japan Society of Hepatology. |